Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 1017-1026

  Lim, Kyu Hyoung ^a,b   Kim, Tae Yong ^a   Lee, Kyung Hun ^a   Han, Sae Won ^a,c   Oh, Do Youn ^a,c   Im, Seock Ah ^a,c   Kim, Tae You ^a,c   Bang, Yung Jue ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Kangwon National University College of Medicine   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Doxorubicin; Gemcitabine pretreated; Mitomycin C; Pancreatic cancer; Prognostic factors

Indexed keywords

CA 19-9 ANTIGEN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CA-19-9 ANTIGEN; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; HEALTH STATUS INDICATORS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; PANCREATIC NEOPLASMS; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80054734886     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1584-1     Document Type: Article

References (41)

1. A Jemal R Siegel E Ward Y Hao J Xu MJ Thun 2009 Cancer Statistics, 2009. CA Cancer J Clin 59 225 249 10.3322/caac.20006
2. JL Cameron TS Riall J Coleman KA Belcher 2006 One thousand consecutive pancreaticoduodenectomies Ann Surg 244 10 15 16794383 10.1097/01.sla.0000217673. 04165.ea
3. SF Sener A Fremgen HR Menck DP Winchester 1999 Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database J Am Coll Surg 189 1 7 10401733 10.1016/S1072-7515(99)00075-7 1:STN:280:DyaK1MzivVWlsg%3D%3D (Pubitemid 29307735)
4. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano MC Cripps RK Portenoy AM Storniolo P Tarassoff R Nelson FA Dorr CD Stephens DD Von Hoff 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 9196156 1:CAS:528:DyaK2sXlsFKksLY%3D (Pubitemid 27251144)
5. CM Rocha Lima D Savarese H Bruckner A Dudek J Eckardt J Hainsworth F Yunus E Lester W Miller W Saville GL Elfring PK Locker LD Compton LL Miller MR Green 2002 Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 1182 1191 11870159 10.1200/JCO.20.5.1182 (Pubitemid 34177423)
6. V Heinemann H Wilke HG Mergenthaler M Clemens H König HJ Illiger M Arning A Schalhorn K Possinger U Fink 2000 Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer Ann Oncol 11 1399 1403 11142479 10.1023/A:1026595525977 1:STN:280:DC%2BD3M7lt12rtw%3D%3D
7. C Louvet T André G Lledo P Hammel H Bleiberg C Bouleuc E Gamelin M Flesch E Cvitkovic A de Gramont 2002 Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study J Clin Oncol 20 1512 1518 11896099 10.1200/JCO.20.6.1512 1:CAS:528:DC%2BD38XivFeitr4%3D (Pubitemid 34260530)
8. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger HJ Au P Murawa D Walde RA Wolff D Campos R Lim K Ding G Clark T Voskoglou-Nomikos M Ptasynski W Parulekar 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 17452677 10.1200/JCO.2006.07.9525 1:CAS:528:DC%2BD2sXmvVWmsr0%3D (Pubitemid 46972777)
9. MH Kulke LS Blaszkowsky DP Ryan JW Clark JA Meyerhardt AX Zhu PC Enzinger EL Kwak A Muzikansky C Lawrence CS Fuchs 2007 Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer J Clin Oncol 25 4787 4792 17947726 10.1200/JCO.2007.11.8521 1:CAS:528:DC%2BD2sXhtlCgsLbO (Pubitemid 350086482)
10. HQ Xiong GR Varadhachary JC Blais KR Hess JL Abbruzzese RA Wolff 2008 Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer Cancer 113 2046 2052 18756532 10.1002/cncr.23810 1:CAS:528:DC%2BD1cXht12lurfE
11. C Yoo JY Hwang JE Kim TW Kim JS Lee DH Park SS Lee DW Seo SK Lee MH Kim DJ Han SC Kim JL Lee 2009 A randomised phase II study of modified FOLFIRI.3 vs. modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer Br J Cancer 101 1658 1663 19826418 10.1038/sj.bjc.6605374 1:CAS:528:DC%2BD1MXhtl2hs7rI
12. BE Fortune X Li KV Kosuri LM Weatherby JP Thomas TS Bekaii-Saab 2009 Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study Oncology 76 333 337 19307739 10.1159/000209962 1:CAS:528:DC%2BD1MXltFWhu7w%3D
13. A Demols M Peeters M Polus R Marechal F Gay E Monsaert A Hendlisz JL Van Laethem 2006 Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study Br J Cancer 94 481 485 16434988 10.1038/sj.bjc.6602966 1:CAS:528:DC%2BD28Xhs1ers78%3D (Pubitemid 43289750)
14. KR Palmer M Kerr G Knowles A Cull DC Carter RC Leonard 1994 Chemotherapy prolongs survival in inoperable pancreatic carcinoma Br J Surg 81 882 885 8044610 10.1002/bjs.1800810629 1:STN:280:DyaK2czhvFyksQ%3D%3D (Pubitemid 24204817)
15. B Glimelius K Hoffman PO Sjödén G Jacobsson H Sellström LK Enander T Linné C Svensson 1996 Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer Ann Oncol 7 593 600 8879373 1:STN:280:DyaK2s%2FjtlOitw%3D%3D (Pubitemid 26285639)
16. FP Smith DF Hoth B Levin DA Karlin JS MacDonald PV Woolley III PS Schein 1980 5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas Cancer 46 2014 2018 7427908 10.1002/1097- 0142(19801101)46:9<2014::AID-CNCR2820460920>3.0.CO;2-D 1:STN:280:DyaL3M%2FktF2ruw%3D%3D (Pubitemid 10025478)
17. SA Cullinan CG Moertel TR Fleming JR Rubin JE Krook LK Everson HE Windschitl DI Twito RF Marschke JF Foley 1985 A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin JAMA 253 2061 2067 2579257 10.1001/jama.253.14.2061 1:STN:280:DyaL2M7jsFalsw%3D%3D (Pubitemid 15102220)
18. Meta-Analysis Group in Cancer 1998 Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer J Clin Oncol 16 301 308
19. Meta-Analysis Group in Cancer 1998 Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors J Clin Oncol 16 3537 3541
20. E Van Cutsem H van de Velde P Karasek H Oettle WL Vervenne A Szawlowski P Schoffski S Post C Verslype H Neumann H Safran Y Humblet J Perez Ruixo Y Ma D Von Hoff 2004 Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer J Clin Oncol 22 1430 1438 15084616 10.1200/JCO.2004.10.112 (Pubitemid 41103625)
21. M Ikeda S Okada K Tokuuye H Ueno T Okusaka 2001 Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy Cancer 91 490 495 11169931 10.1002/1097-0142(20010201)91:3<490::AID- CNCR1027>3.0.CO;2-L 1:STN:280:DC%2BD3M7ktFOhtQ%3D%3D (Pubitemid 32105694)
22. TE Ciuleanu AV Pavlovsky G Bodoky AM Garin VK Langmuir S Kroll GT Tidmarsh 2009 A randomised phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine Eur J Cancer 45 1589 1596 19188061 10.1016/j.ejca.2008.12.022 1:CAS:528:DC%2BD1MXms1WmtLo%3D
23. R Maréchal A Demols F Gay V De Maertelaere M Arvanitaki A Hendlisz JL Van Laethem 2007 Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer Oncology 73 41 51 18334830 10.1159/000120627 (Pubitemid 351465599)
24. L Dahan F Bonnetain M Ychou E Mitry M Gasmi JL Raoul S Cattan JM Phelip P Hammel B Chauffert P Michel JL Legoux P Rougier L Bedenne JF Seitz 2010 Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301) Gut 59 1527 1534 20947887 10.1136/gut.2010.216135 1:CAS:528:DC%2BC3cXhsFemurjO
25. N Tsavaris C Kosmas H Skopelitis P Gouveris P Kopterides D Loukeris F Sigala A Zorbala-Sypsa E Felekouras E Papalambros 2005 Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study Invest New Drugs 23 369 375 16012797 10.1007/s10637-005-1446-y 1:CAS:528:DC%2BD2MXmtVymtb4%3D (Pubitemid 40980360)
26. M Cantore C Rabbi G Fiorentini C Oliani D Zamagni C Iacono A Mambrini A Del Freo A Manni 2004 Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer Oncology 67 93 97 15539911 10.1159/000080993 1:CAS:528:DC%2BD2cXpslWit70%3D (Pubitemid 39482675)
27. M Reni L Pasetto G Aprile S Cordio E Bonetto S Dell'Oro P Passoni L Piemonti C Fugazza G Luppi C Milandri R Nicoletti A Zerbi G Balzano V Di Carlo AA Brandes 2006 Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer Br J Cancer 94 785 791 16508631 10.1038/sj.bjc.6603026 1:CAS:528:DC%2BD28Xis1Gktb4%3D
28. U Pelzer K Kubica J Stieler I Schwaner G Heil M Görner M Mölle A Hilbig B Dörken H Riess H Oettle 2008 A randomized trial in patients with gemcitabine-refractory pancreatic cancer. Final results of the CONKO 003 study (abstract) J Clin Oncol 26 215s
29. JS MacDonald PV Woolley T Smythe W Ueno D Hoth PS Schein 1979 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer Cancer 44 42 47 455263 10.1002/1097-0142(197907)44:1<42::AID-CNCR2820440108>3.0.CO;2-X 1:STN:280:DyaE1M3htV2itQ%3D%3D (Pubitemid 9234907)
30. ST Crooke WT Bradner 1976 Mitoycin C: a review Cancer Treat Rev 3 121 139 786455 10.1016/S0305-7372(76)80019-9 1:STN:280:DyaE2s%2FgtFCruw%3D%3D
31. N Maisey I Chau D Cunningham A Norman M Seymour T Hickish T Iveson M O'Brien N Tebbutt A Harrington M Hill 2002 Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer J Clin Oncol 20 3130 3136 12118027 10.1200/JCO.2002.09.029 1:CAS:528:DC%2BD38XmtVCrtbs%3D (Pubitemid 34791103)
32. AC Sartorelli BA Boothe 1965 The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil Cancer Res 25 1393 1400 5861069 1:CAS:528:DyaF28XmsVCm
33. PS Schein PT Lavin CG Moertel 1978 Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report Cancer 42 19 22 352505 10.1002/1097-0142(197807)42:1<19::AID-CNCR2820420103>3.0.CO;2-4 1:STN:280:DyaE1c3ht1Kmsg%3D%3D (Pubitemid 9031838)
34. J Wils H Bleiberg G Blijham O Dalesio N Duez A Lacave T Splinter 1985 Phase II study of epirubicin in advanced adenocarcinoma of the pancreas Eur J Cancer Clin Oncol 21 191 194 3857181 10.1016/0277-5379(85)90172-5 1:STN:280:DyaL2M7nvFKmsA%3D%3D (Pubitemid 15169692)
35. K Nakachi J Furuse H Ishii E Suzuki M Yoshino 2007 Prognostic factors in patients with gemcitabine-refractory pancreatic cancer Jpn J Clin Oncol 37 114 120 17272317 10.1093/jjco/hyl144 (Pubitemid 47090708)
36. P Magistrelli A Antinori A Crucitti A La Greca R Masetti R Coppola G Nuzzo A Picciocchi 2000 Prognostic factors after surgical resection for pancreatic carcinoma J Surg Oncol 74 36 40 10861607 10.1002/1096-9098(200005)74: 1<36::AID-JSO9>3.0.CO;2-F 1:STN:280:DC%2BD3czitFCktg%3D%3D (Pubitemid 30387220)
37. H Ueno S Okada T Okusaka M Ikeda 2000 Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy Oncology 59 296 301 11096341 10.1159/000012186 1:STN:280:DC%2BD3M%2FnvVWntQ%3D%3D
38. AH Ko J Hwang AP Venook JL Abbruzzese EK Bergsland MA Tempero 2005 Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer Br J Cancer 93 195 199 15999098 10.1038/sj.bjc.6602687 1:CAS:528:DC%2BD2MXmt1yhurs%3D (Pubitemid 41133205)
39. NR Maisey AR Norman A Hill A Massey J Oates D Cunningham 2005 CA 19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials Br J Cancer 93 740 743 16175188 10.1038/sj.bjc.6602760 1:CAS:528:DC%2BD2MXhtVeksbvE (Pubitemid 41486431)
40. C Ziske C Schlie M Gorschlüter A Glasmacher U Mey J Strehl T Sauerbruch IG Schmidt-Wolf 2003 Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine Br J Cancer 89 1413 1417 14562009 10.1038/sj.bjc.6601263 1:CAS:528: DC%2BD3sXotFeksL8%3D (Pubitemid 37386593)
41. GY Locker S Hamilton J Harris JM Jessup N Kemeny JS Macdonald MR Somerfield DF Hayes RC Bast Jr 2006 ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer J Clin Oncol 24 5313 5327 17060676 10.1200/JCO.2006.08.2644 1:CAS:528:DC%2BD28XhtlemurfN (Pubitemid 46631379)